General Information of Drug (ID: DMPGLIO)

Drug Name
Donanemab Drug Info
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMPGLIO

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nirogacestat DMUP5Z0 Desmoid tumour 2F7C Approved [3]
Aducanumab DM51JW4 Alzheimer disease 8A20 Approved [4]
Lecanemab DMW03YD Alzheimer disease 8A20 Approved [5]
Florbetapir F-18 DMJ8A3Z Diagnostic imaging N.A. Approved [6]
GV-971 DMTMA5W Alzheimer disease 8A20 Approved in China [7]
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [8]
Solanezumab DM0HIU5 Alzheimer disease 8A20 Phase 3 [9]
Tramiprosate DM7BSRH Alzheimer disease 8A20 Phase 3 [10]
Bapineuzumab DMHQ5GK Alzheimer disease 8A20 Phase 3 [11]
ALZT-OP1 DMG5BTD Alzheimer disease 8A20 Phase 3 [12]
Nirogacestat DMUP5Z0 Desmoid tumour 2F7C Approved [3]
Aducanumab DM51JW4 Alzheimer disease 8A20 Approved [4]
Lecanemab DMW03YD Alzheimer disease 8A20 Approved [5]
Florbetapir F-18 DMJ8A3Z Diagnostic imaging N.A. Approved [6]
GV-971 DMTMA5W Alzheimer disease 8A20 Approved in China [7]
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [8]
Solanezumab DM0HIU5 Alzheimer disease 8A20 Phase 3 [9]
Tramiprosate DM7BSRH Alzheimer disease 8A20 Phase 3 [10]
Bapineuzumab DMHQ5GK Alzheimer disease 8A20 Phase 3 [11]
ALZT-OP1 DMG5BTD Alzheimer disease 8A20 Phase 3 [12]
⏷ Show the Full List of 20 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Amyloid beta A4 protein (APP) TTE4KHA A4_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT05108922) A Phase 3, Open-Label, Parallel-Group, 2-Arm Study to Investigate Amyloid Plaque Clearance With Donanemab Compared With Aducanumab-avwa in Participants With Early Symptomatic Alzheimer's Disease. U.S.National Institutes of Health.
2 Donanemab in Early Alzheimer's Disease. N Engl J Med. 2021 May 6;384(18):1691-1704.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets . Immun Ageing. 2013; 10: 18.
5 The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2015;43(2):575-88.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
7 Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression. Cell Res. 2019 Oct;29(10):787-803.
8 Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem. 2006 Oct 5;49(20):6111-9.
9 Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370(4):311-21.
10 Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007 Apr;28(4):537-47.
11 Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy. 2010 Nov;2(6):767-82.
12 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)